HISTOGENICS CORPORATION (NASDAQ:HSGX) Files An 8-K Other Events

Item8.01.

On June 27, 2017, Histogenics Corporation (Histogenics) issued a
press release announcing that it has completed enrollment of its
Phase 3 clinical trial of NeoCart, an investigational product
designed to repair and replace damaged cartilage, initially in
the knee.

The press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated herein by reference.

HISTOGENICS CORP Exhibit
EX-99.1 2 d261386dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   HISTOGENICS COMPLETES ENROLLMENT FOR PHASE 3 CLINICAL TRIAL OF NEOCART® TO TREAT KNEE CARTILAGE DAMAGE – On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – – Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain through Proprietary Process that Replicates the Body’s Ability to Grow Cartilage as a Juvenile – WALTHAM,…
To view the full exhibit click here
About HISTOGENICS CORPORATION (NASDAQ:HSGX)

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.